-Ian M Thompson Researcher Activity Profile

Research Author Detailed Information 

Ian M Thompson Publication Rate By Year

Ian M Thompson has published 1 paper(s) in 1958, 1 paper(s) in 1959, 3 paper(s) in 2006, 38 paper(s) in 2007, 9 paper(s) in 2008, for a total of 52 research publications in total.

Ian M Im Thompson Author Information

LAST NAME: thompson

FIRST NAME: Ian M

INITIALS: im

AFFILIATION:

Papers

Ian M Thompson's Publication Record

1. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. thompsoni@uthscsa.edu
2. Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men. Year Published: 2007
Division of Gerontology and Geriatric Medicine, Department of Medicine, the University of Alabama at Birmingham, Birmingham, Alabama, USA.
3. Prostate cancer detection strategies. Year Published: 2006
Department of Urology, University of Texas Health Science Center, Mail Code 7845, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. brandt2@uthscsa.edu
4. Flare Associated with LHRH-Agonist Therapy. Year Published: 2006
5. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Year Published: 2006
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M4-B402, Seattle, WA 98109-1024, USA. zgong@fhcrc.org
6. Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers. Year Published: 2007
7. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Year Published: 2007
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. akristal@fhcrc.org
8. Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. Year Published: 2007
9. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7802, USA. parekhd@uthscsa.edu
10. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. Year Published: 2007
Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA. gswanson@ctrc.net
11. Finasteride decreases the risk of prostatic intraepithelial neoplasia. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio and Southwest Oncology Group, San Antonio, Texas 78229, USA. thompsoni@uthscsa.edu
12. Prostate-specific antigen in the early detection of prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Tex 78229, USA. thompsoni@uthscsa.edu
13. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. thompsoni@uthscsa.edu
14. Urologists' attitudes regarding cancer clinical research. Year Published: 2007
Department of Radiation Oncology, University of Texas Health Science Center San Antonio, San Antonio, Texas 78229, USA. gswanson@ctrc.net
15. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. Year Published: 2007
Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B-216, Denver, CO 80262, USA. scott.lucia@uchsc.edu
16. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Year Published: 2007
Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, Texas 78229-3900, USA.
17. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Year Published: 2007
Urology Service, Department of Surgery, Brooke Army Medical Center, Fort Sam Houston,TX 78234-6200, USA.
18. Adjuvant radiotherapy for high-risk patients following radical prostatectomy. Year Published: 2007
Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
19. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7802, USA. parekhd@uthscsa.edu
20. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Sciences Center-San Antonio, San Antonio, Texas 78229, USA.
21. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. Year Published: 2007
Translational and Outcomes Research Group, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, M2-B230, PO Box 19024, Seattle, WA 98109, USA. retzioni@fhcrc.org
22. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
23. Biomarkers for prostate cancer detection. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7802, USA. parekhd@uthscsa.edu
24. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Year Published: 2007
The Sandra and Stanley Rosenberg Family Laboratories, Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
25. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. Year Published: 2007
Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA. gswanson@ctrc.net
26. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
27. Health-related quality of life results in pathologic stage C prostate cancer from a southwest oncology group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. Year Published: 2007
Corresponding author: Carol M. Moinpour, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, M3-C102, 1100 Fairview Ave North, Box 19024, Seattle, WA 98109-1024; e-mail: cmoinpou@fhcrc.org.
28. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Year Published: 2007
Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, Texas 78229-3900, USA.
29. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Year Published: 2007
The Sandra and Stanley Rosenberg Family Laboratories, Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
30. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA.
31. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Year Published: 2007
Urology Service, Department of Surgery, Brooke Army Medical Center, Fort Sam Houston,TX 78234-6200, USA.
32. Biomarkers for prostate cancer detection. Year Published: 2007
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7802, USA. parekhd@uthscsa.edu
33. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. Year Published: 2007
Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
34. Association of polymorphisms in TGFB1 and prostate cancer prognosis. Year Published: 2008
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
35. Adjuvant radiotherapy for high-risk patients following radical prostatectomy. Year Published: 2007
Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. gswanson@ctrc.net
36. Finasteride, prostate cancer, and weight gain: Evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Year Published: 2008
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
37. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7802, USA. parekhd@uthscsa.edu
38. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Year Published: 2007
Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7802, USA. parekhd@uthscsa.edu
39. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
40. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
41. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. Year Published: 2007
Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
42. Integrating the predictiveness of a marker with its performance as a classifier. Year Published: 2008
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. mspepe@u.washington.edu
43. The effect of race/ethnicity on the accuracy of the 2001 partin tables for predicting pathologic stage of localized prostate cancer. Year Published: 2008
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
44. Association of polymorphisms in TGFB1 and prostate cancer prognosis. Year Published: 2008
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
45. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Year Published: 2008
Barbara Ann Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA. heathe@karmanos.org
46. Integrating the predictiveness of a marker with its performance as a classifier. Year Published: 2008
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. mspepe@u.washington.edu
47. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
48. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
49. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Year Published: 2008
Barbara Ann Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA. heathe@karmanos.org
50. The role of spinal cord traction in the neurovesical dysfunction of spina bifida. Year Published: 1958
51. Furadantin: a reassessment in the light of excretion studies. Year Published: 1959
52. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Year Published: 2008
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.